Veteran Affairs Boston Healthcare System, Boston, MA, United States.
San Carlo di Nancy Hospital, Rome, Italy.
Actas Urol Esp (Engl Ed). 2021 Jun;45(5):345-352. doi: 10.1016/j.acuroe.2021.04.011. Epub 2021 May 14.
The novel da Vinci Single-Port (SP) robotic platform received the US FDA approval in 2018. The device, specifically conceived for single-site approach, is pushing through the limits of minimally invasive surgery. We sought to provide a comprehensive overview of the current status of the clinical experiences accomplished by the da Vinci SP in urology, and to discuss future perspectives.
A non-systematic literature review was performed focusing on single port articles in urological surgery using Medline/PubMed and Embase search electronic engines. The authors analyzed findings and a brief report of the clinical experience for surgical procedures completed by the SP platform was described.
The current data available from single-port robotic established the safety and feasibility of urologic procedures using this novel platform. However, the results come from single-center case series, small cohorts and retrospective studies that need to be cautiously interpreted. Additional evidence is required to determine the asset of the SP platform in the urological community.
The SP robotic system opens new frontiers on the surgical scenery facilitating the completion of urological surgeries through a single incision. Further comparative studies will be required to assess perioperative and long-term oncological and functional outcomes among SP, multi-arm robotic and open approaches.
新型达芬奇单端口（SP）机器人平台于 2018 年获得美国 FDA 批准。该设备专为单部位入路而设计，正在突破微创手术的极限。我们旨在提供达芬奇 SP 在泌尿外科中完成的临床经验的全面概述，并讨论未来的前景。
使用 Medline/PubMed 和 Embase 搜索电子引擎，我们对泌尿外科单端口文章进行了非系统性文献回顾。作者分析了研究结果，并简要报告了 SP 平台完成的手术的临床经验。
目前来自单端口机器人的现有数据证实了使用这种新型平台进行泌尿外科手术的安全性和可行性。然而，这些结果来自单中心病例系列、小队列和回顾性研究，需要谨慎解释。需要更多的证据来确定 SP 平台在泌尿外科领域的优势。
SP 机器人系统为手术场景开辟了新的领域，通过单一切口促进了泌尿外科手术的完成。需要进一步的比较研究来评估 SP、多臂机器人和开放方法之间的围手术期和长期肿瘤学及功能结果。
